Last updated on May 2018

CHEckpoint Inhibition in Combination With an Immunoboost of External Body Radiotherapy in Solid Tumors


Brief description of study

This randomized controlled phase II trial will investigate whether the addition of stereotactic body radiotherapy to checkpoint inhibitor treatment in patients with non-small-cell lung carcinoma, urothelial carcinoma, renal cell carcinoma, melanoma or head-and-neck carcinoma can improve progression-free survival as compared to checkpoint inhibitor monotherapy. The primary outcome is progression-free survival; secondary outcomes include overall survival, response according to iRecist and Recist v1.1 and toxicity.

Clinical Study Identifier: NCT03511391

Find a site near you

Start Over